Healio quotes Michael Dwyer in an article about a drug, Ocrelizumab, that significantly reduced the number and volume of ...

Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

Please provide your email address to receive an email when new articles are posted on . Ocrelizumab reduced the number and size of MS-related cortical lesions. Data synthesis featuring a mix of ...

There is growing clinical evidence that aHSCT can treat RRMS more effectively than DMTs. However, as most data is registry-based and previous trials did not directly compare aHSCT with the most ...

Ocrevus (ocrelizumab) is a prescription drug that treats certain types of multiple sclerosis (MS) in adults by lowering B cell levels. Your response to this drug may vary based on your medical ...